Shandong Xinhua Pharmaceutical (00719) Secures Drug Registration Certificate for Ketorolac Tromethamine Injection

Stock News

Nov 06

Shandong Xinhua Pharmaceutical (00719) has announced that the company recently received the Drug Registration Certificate for Ketorolac Tromethamine Injection approved and issued by the National Medical Products Administration.

This product is indicated for short-term treatment (not exceeding 5 days) of moderate to severe acute pain in adults requiring opioid-level analgesia, and is typically used for postoperative pain relief. The product belongs to Category B of the National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Drug Catalog (2025).

According to relevant statistics, the sales of Ketorolac Tromethamine Injection in Chinese public medical institutions in 2025 amounted to approximately RMB 230 million. The Ketorolac Tromethamine Injection of Shandong Xinhua Pharmaceutical obtained the Drug Registration Certificate in November 2026, which is conducive to enriching the company's analgesic product series and enhancing the company's market competitiveness.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1114213180"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1114213180\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1114213180?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-11-06 16:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114213180","market":"fut","top_or_hot":-1,"title":"Shandong Xinhua Pharmaceutical (00719) Secures Drug Registration Certificate for Ketorolac Tromethamine Injection","media":"Stock News","content":"<p>Shandong Xinhua Pharmaceutical (00719) has announced that the company recently received the Drug Registration Certificate for Ketorolac Tromethamine Injection approved and issued by the National Medical Products Administration.<br><br>This product is indicated for short-term treatment (not exceeding 5 days) of moderate to severe acute pain in adults requiring opioid-level analgesia, and is typically used for postoperative pain relief. The product belongs to Category B of the National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Drug Catalog (2025).<br><br>According to relevant statistics, the sales of Ketorolac Tromethamine Injection in Chinese public medical institutions in 2025 amounted to approximately RMB 230 million. The Ketorolac Tromethamine Injection of Shandong Xinhua Pharmaceutical obtained the Drug Registration Certificate in November 2026, which is conducive to enriching the company's analgesic product series and enhancing the company's market competitiveness.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shandong Xinhua Pharmaceutical (00719) Secures Drug Registration Certificate for Ketorolac Tromethamine Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShandong Xinhua Pharmaceutical (00719) Secures Drug Registration Certificate for Ketorolac Tromethamine Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-11-06 16:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shandong Xinhua Pharmaceutical (00719) has announced that the company recently received the Drug Registration Certificate for Ketorolac Tromethamine Injection approved and issued by the National Medical Products Administration.<br><br>This product is indicated for short-term treatment (not exceeding 5 days) of moderate to severe acute pain in adults requiring opioid-level analgesia, and is typically used for postoperative pain relief. The product belongs to Category B of the National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Drug Catalog (2025).<br><br>According to relevant statistics, the sales of Ketorolac Tromethamine Injection in Chinese public medical institutions in 2025 amounted to approximately RMB 230 million. The Ketorolac Tromethamine Injection of Shandong Xinhua Pharmaceutical obtained the Drug Registration Certificate in November 2026, which is conducive to enriching the company's analgesic product series and enhancing the company's market competitiveness.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1114213180","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114213180","pubTimestamp":1793955275,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shandong Xinhua Pharmaceutical (00719) has announced that the company recently received the Drug Registration Certificate for Ketorolac Tromethamine Injection approved and issued by the National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1515":"抗疫概念","00719":"山东新华制药股份"},"translate_title":"山东新华制药(00719)获酮咯酸氨丁三醇注射液药品注册证","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00719":1},"content_text":"Shandong Xinhua Pharmaceutical (00719) has announced that the company recently received the Drug Registration Certificate for Ketorolac Tromethamine Injection approved and issued by the National Medical Products Administration.This product is indicated for short-term treatment (not exceeding 5 days) of moderate to severe acute pain in adults requiring opioid-level analgesia, and is typically used for postoperative pain relief. The product belongs to Category B of the National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Drug Catalog (2025).According to relevant statistics, the sales of Ketorolac Tromethamine Injection in Chinese public medical institutions in 2025 amounted to approximately RMB 230 million. The Ketorolac Tromethamine Injection of Shandong Xinhua Pharmaceutical obtained the Drug Registration Certificate in November 2026, which is conducive to enriching the company's analgesic product series and enhancing the company's market competitiveness.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}